In a historic achievement, the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) has successfully completed clinical trials of Supernova, a next-generation mechanical thrombectomy device designed to remove blood clots from brain arteries in stroke patients.
According to Dr. Sunil Narayan, Head of the Department of Neurology at JIPMER, the device was developed by Indian-origin engineers and interventional radiologists in the United States, in collaboration with a manufacturing facility in Hyderabad. The Drug Controller General of India (DCGI) has now approved Supernova for commercial use in the country.
The results of the GRASSROOT trial, which evaluated the device, were presented at the World Stroke Congress held in Barcelona from October 22 to 24. The Supernova device demonstrated safety and efficacy comparable to expensive imported systems currently used for stroke treatment.
Being manufactured in India, Supernova is expected to cost 50–70% less than imported devices, significantly reducing treatment expenses and making advanced stroke therapy more accessible to public hospitals and patients in low- and middle-income countries.
This milestone comes as the world observes World Stroke Day under the theme “Act Fast: Every Minute Counts.” Doctors emphasize that early intervention is critical — clot-dissolving drugs work best within 3 to 4.5 hours of stroke onset, while mechanical thrombectomy offers hope for patients who arrive within six to seven hours of symptoms.
Also Read
